Zacks Investment Research upgraded shares of Lantheus (NASDAQ:LNTH) from a hold rating to a buy rating in a report issued on Wednesday. Zacks Investment Research currently has $21.00 price objective on the medical equipment provider’s stock.
According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “
LNTH has been the topic of a number of other reports. BidaskClub raised shares of Lantheus from a hold rating to a buy rating in a report on Thursday, November 22nd. ValuEngine downgraded shares of Lantheus from a buy rating to a hold rating in a report on Wednesday, January 2nd. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Lantheus has an average rating of Buy and an average target price of $20.67.
LNTH opened at $22.03 on Wednesday. The company has a current ratio of 3.50, a quick ratio of 2.87 and a debt-to-equity ratio of 4.76. The firm has a market cap of $736.99 million, a price-to-earnings ratio of 19.96, a PEG ratio of 3.87 and a beta of 1.47. Lantheus has a 1 year low of $12.59 and a 1 year high of $22.50.
Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Tuesday, February 19th. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.09. The firm had revenue of $86.27 million for the quarter, compared to the consensus estimate of $83.93 million. Lantheus had a net margin of 11.80% and a return on equity of 83.91%. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.47 EPS. On average, analysts expect that Lantheus will post 0.99 EPS for the current fiscal year.
In other Lantheus news, CEO Mary Anne Heino sold 9,564 shares of Lantheus stock in a transaction on Wednesday, January 30th. The shares were sold at an average price of $16.47, for a total transaction of $157,519.08. Following the transaction, the chief executive officer now directly owns 630,782 shares of the company’s stock, valued at approximately $10,388,979.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Cesare Orlandi sold 3,060 shares of Lantheus stock in a transaction on Thursday, January 31st. The stock was sold at an average price of $16.56, for a total value of $50,673.60. Following the sale, the insider now owns 77,746 shares in the company, valued at $1,287,473.76. The disclosure for this sale can be found here. Insiders have sold a total of 23,736 shares of company stock worth $408,523 over the last ninety days. Insiders own 1.20% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in LNTH. PNC Financial Services Group Inc. raised its stake in shares of Lantheus by 51.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,694 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 575 shares during the period. Financial Gravity Companies Inc. bought a new stake in shares of Lantheus during the 4th quarter worth $45,000. Advisor Group Inc. raised its stake in shares of Lantheus by 1,837.2% during the 4th quarter. Advisor Group Inc. now owns 4,378 shares of the medical equipment provider’s stock worth $69,000 after purchasing an additional 4,152 shares during the period. Gotham Asset Management LLC bought a new stake in shares of Lantheus during the 4th quarter worth $165,000. Finally, Municipal Employees Retirement System of Michigan bought a new stake in shares of Lantheus during the 4th quarter worth $171,000. Institutional investors own 94.69% of the company’s stock.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
Featured Article: Why is Cost of Capital Important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.